Analyst Price Target is $201.25
▲ +63.97% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DiaSorin in the last 3 months. The average price target is $201.25, with a high forecast of $201.25 and a low forecast of $201.25. The average price target represents a 63.97% upside from the last price of $122.74.
Current Consensus is
The current consensus among 5 polled investment analysts is to hold stock in DiaSorin. This rating has held steady since November 2020, when it changed from a Buy consensus rating.
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.